We are delighted to share that the review “MYC in cancer: from undruggable target to clinical trials” by Jonathan Whitfield and Laura Soucek is finally out in Nature Reviews Drug Discovery. What an amazing journey this has been and still promises to be! rdcu.be/eawOK

#MYC: from undruggable target to the first cancer clinical trials 🔬 🗞️ Recently published as a Review Article in Nature Reviews Drug Discovery, Laura Soucek and Jonathan Whitfield provide an expert overview of the different strategies to inhibit MYC. ➡️ linke.to/MYNRDD_VHIO

#MYC: de diana terapéutica intratable a los primeros ensayos clínicos en pacientes con cáncer 🔬 🗞️ Recientemente publicado como artículo de revisión en Nature Reviews Drug Discovery, Laura Soucek y Jonathan Whitfield ofrecen una visión experta sobre las diferentes estrategias para inhibir MYC ➡️

#MYC: de diana terapèutica intractable als primers assaigs clínics en pacients amb càncer 🔬 Laura Soucek i Jonathan Whitfield han coliderat un article publicat a Nature Reviews Drug Discovery que analitza els esforços de la comunitat científica per desenvolupar aquest fàrmac. ➡️

#ESMOTAT25 📣 The corporate and investor mindset: What types of anticancer drugs and clinical research proposals will be prioritized in the near term? 💬 Laura Soucek, Cristian Massacesi, Shaily Arora, Yael Gruenbaum Cohen & Giovanni Abbadessa. 👉 esmo.org/meeting-calend…

Congratulations to our Daniel Capitán for being awarded a Fundación ”la Caixa” PhD fellowship! We are all proud of you 👏

¿Sabías que el plasma es clave para muchos tratamientos médicos❓ En VHIO nos sumamos al #RepteDor Banc de Sang para aumentar las donaciones de plasma en Cataluña 👇 #ViuiFesViure

Spring has sprung: LSoucekLab and PEPTOMYC celebrate their annual calçotada/asado with friends, spouses, kids and dogs. <3

VHIO researchers Laura Soucek, Seoane Lab, ToledoLab_VHIO & Julia Montoro participated in the Amgen 🧪🔬🧬 Partners of Choice meeting in Reykjavík to share projects, foster collaboration, and accelerate new cancer therapies. Teamwork and innovation are key to improving patient outcomes‼️

#AACR25 | Laura Soucek, Director of VHIO’s Preclinical and Translational Research Program, has chaired and spoken at the AACR Annual Meeting on strategies to target MYC, one of the most challenging targets in cancer research. #CancerResearch

#AACR25 | On Tuesday, April 29, at AACR, Fabio Giuntini, researcher in VHIO’s Models of Cancer Therapies Group, will present on how Omomyc synergizes with PARPi and reverts resistance to therapy in multiple PARPi-resistant triple-negative breast cancer models.

Our PhD student (not for much longer!), Fabio Giuntini, just presented a poster at #AACR25 regarding DNA damage modulation by MYC inhibition as a new therapeutic opportunity in TNBC. He’s also been selected for an oral presentation tomorrow. Stay tuned! Vall d’Hebron Institute of Oncology (VHIO)

Wonderful presentation by Fabio Giuntini at #AACR25 in the minisymposium Experimental Therapeutics: Drug Resitance, talking about Omomyc synergy with PARPi in PARPi-resistant TNBC. We are so proud! Vall d’Hebron Institute of Oncology (VHIO)

This is definitely something to cellebrate! A triumph of science: a real impact on a baby that did not have any chance to make it. So inspiring. I hope also inspiring to those that question the role science must have in all societies. Long live to KJ! nytimes.com/2025/05/15/hea…

Proud to see our Íñigo González Larreategui presenting a poster about the therapeutic impact and reactivation of tumor immunity by MYC inhibition in KRAS-driven NSCLC with diverse mutational profiles at the #EACR Congress: Defence is the best attack: Immuno-Oncology Breakthroughs 2025. Great work!

Our CEO Laura Soucek and our CSO Marie-Eve Beaulieu are at #BIO2025 in Boston! Let’s connect and talk MYC inhibition and novel cancer therapies. #Peptomyc #oncology #VHIO

We are proud to announce that our PhD student, Daniel Capitán, presented yesterday a poster at #EACR2025 in Lisbon titled “MYC targeting by Omomyc boosts efficacy and overcomes resistance to KRAS inhibitors”. Well done, Dani! Vall d’Hebron Institute of Oncology (VHIO) EACR #cancer

What a day in the LSoucekLab! Fabio Giuntini defended his PhD and made us all proud. Big thanks to sara sdelci, Judit Balmaña and Stefano Campaner for being part of the PhD thesis committee. Congratulations, Dr Giuntini!

Thrilled to receive an European Research Council (ERC) #ProofOfConcept grant for our #SONOMYC project! 🚀 We’ll explore ultrasound-enabled delivery of #OMO103 to the brain, targeting #MYC in primary & metastatic brain tumors. 🙏 🔗 lnkd.in/djFXaiTB Vall d’Hebron Institute of Oncology (VHIO) ICREA Community PEPTOMYC

🔬 En VHIO trabajamos para transformar los últimos hallazgos del laboratorio en #EnsayosClínicos iniciales que den lugar a mejores tratamientos para los pacientes.  Ayúdanos a seguir avanzando, haz tu donación aquí 👉 linke.to/DonacionVHIO #Investigacióndelcáncer